Denali Therapeutics Inc. (DNLI) earnings
DNLI earnings moved a median of +0.93% by the close. Quarterly and annual DNLI reports and results, each read against the price at its own news timestamp. Back to the DNLI overview →
22 measured DNLI earnings events.
Where these DNLI earnings landedvs 20 measured DNLI earnings reactions
| Middle 50% of DNLI earnings reactions | -1.98% to +2.65% |
|---|---|
| Median reaction (to close) | +0.93% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 DNLI earnings events with a measured close landed between -1.98% and +2.65%; 70% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | -0.63% | -2.51% | |
| Form 10-Q Denali Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.63% | -2.51% | |
| Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 | Press release | -0.42% | +0.54% | |
| Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | Press release | +2.29% | +0.93% | |
| Form 10-Q Denali Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.29% | +0.93% | |
| Form 10-K Denali Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -2.59% | +1.44% | |
| Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | +1.19% | +5.26% | |
| Form 10-Q Denali Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.19% | +5.26% | |
| Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | -1.64% | — | |
| Form 10-Q Denali Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.64% | — | |
| Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome | Press release | -0.25% | +2.65% | |
| Form 10-Q Denali Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.25% | +2.65% | |
| Form 10-K Denali Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -3.98% | -12.05% | |
| Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | Press release | +2.77% | +1.20% | |
| Form 10-Q Denali Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.77% | +1.20% | |
| Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | Press release | +1.51% | -1.98% | |
| Form 10-Q Denali Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.51% | -1.98% | |
| Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | Press release | +4.62% | +11.18% | |
| Form 10-Q Denali Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +4.62% | +11.18% | |
| Form 10-K Denali Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -3.06% | -10.22% | |
| Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights | Press release | -2.69% | +0.70% | |
| Form 10-Q Denali Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.69% | +0.70% |
Keep exploring
More DNLI: analyst actions → · SEC filings → · DNLI overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Senseonics Holdings, Inc. (SENS) | 318 | -0.44% | 42% |
| Allogene Therapeutics, Inc. (ALLO) | 316 | +0.18% | 51% |
| Myomo Inc. (MYO) | 315 | +0.35% | 54% |
| ICU Medical, Inc. (ICUI) | 313 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.